142 related articles for article (PubMed ID: 30826010)
21. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction.
Bristow RE; Eisenhauer EL; Santillan A; Chi DS
Gynecol Oncol; 2007 Feb; 104(2):480-90. PubMed ID: 17166564
[TBL] [Abstract][Full Text] [Related]
22. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
23. Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Propensity-matched Analysis.
Siesto G; Cavina R; Romano F; Vitobello D
Am J Clin Oncol; 2018 Mar; 41(3):280-285. PubMed ID: 26757434
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.
Taşkın S; Güngör M; Ortaç F; Öztuna D
Arch Gynecol Obstet; 2013 Dec; 288(6):1399-403. PubMed ID: 23775264
[TBL] [Abstract][Full Text] [Related]
25. Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer.
Lee YY; Lee JW; Lu L; Xu W; Kollara A; Brown T; Heo EJ; May T
Int J Gynaecol Obstet; 2018 Dec; 143(3):325-332. PubMed ID: 30129040
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
Wright AA; Bohlke K; Armstrong DK; Bookman MA; Cliby WA; Coleman RL; Dizon DS; Kash JJ; Meyer LA; Moore KN; Olawaiye AB; Oldham J; Salani R; Sparacio D; Tew WP; Vergote I; Edelson MI
J Clin Oncol; 2016 Oct; 34(28):3460-73. PubMed ID: 27502591
[TBL] [Abstract][Full Text] [Related]
27. 3-4 Cycles vs 6 Cycles NACT in Advanced Stage Epithelial Ovarian Cancer: Survival is not Determined by the Number of NACT Cycles.
Bese T; Bicer E; Kayan BO; Cebi SS; Acikgoz AS; Turna H; Demirkiran F
Chemotherapy; 2023 Dec; ():. PubMed ID: 38113873
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
[TBL] [Abstract][Full Text] [Related]
29. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
[TBL] [Abstract][Full Text] [Related]
30. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
Petrillo M; Zannoni GF; Tortorella L; Pedone Anchora L; Salutari V; Ercoli A; Margariti PA; Scambia G; Fagotti A
Am J Obstet Gynecol; 2014 Dec; 211(6):632.e1-8. PubMed ID: 24954656
[TBL] [Abstract][Full Text] [Related]
31. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
32. Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications.
Bhatt A; Bakrin N; Kammar P; Mehta S; Sinukumar S; Parikh L; Shaikh S; Mishra S; Mallaya M; Kepenekian V; Benzerdjeb N; Glehen O
Eur J Surg Oncol; 2021 Jan; 47(1):181-187. PubMed ID: 33071172
[TBL] [Abstract][Full Text] [Related]
33. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
[TBL] [Abstract][Full Text] [Related]
34. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
[TBL] [Abstract][Full Text] [Related]
36.
Vallius T; Hynninen J; Kemppainen J; Alves V; Auranen K; Matomäki J; Oksa S; Virtanen J; Grénman S; Auranen A; Seppänen M
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1224-1232. PubMed ID: 29476227
[TBL] [Abstract][Full Text] [Related]
37. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer.
Kessous R; Laskov I; Abitbol J; Bitharas J; Yasmeen A; Salvador S; Lau S; Gotlieb WH
Gynecol Oncol; 2017 Mar; 144(3):474-479. PubMed ID: 28041690
[TBL] [Abstract][Full Text] [Related]
40. Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes.
Nero C; Fagotti A; Zannoni GF; Palluzzi E; Scambia G; Petrillo M
Int J Gynecol Cancer; 2019 Jul; 29(6):1064-1071. PubMed ID: 31061096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]